335 related articles for article (PubMed ID: 28860113)
1. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.
Huang W; Nakano M; Sager J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2017 Nov; 45(11):1156-1165. PubMed ID: 28860113
[TBL] [Abstract][Full Text] [Related]
2. Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.
Notsu Y; Shimizu M; Sasaki T; Nakano A; Ota M; Yoshida S; Yamazaki H
Drug Metab Pharmacokinet; 2020 Apr; 35(2):191-200. PubMed ID: 32184039
[TBL] [Abstract][Full Text] [Related]
3. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.
Kim SH; Byeon JY; Kim YH; Lee CM; Lee YJ; Jang CG; Lee SY
Sci Rep; 2018 Aug; 8(1):12405. PubMed ID: 30120390
[TBL] [Abstract][Full Text] [Related]
5. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 May; 47(5):481-504. PubMed ID: 38664354
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Chen Y; Zhou D; Tang W; Zhou W; Al-Huniti N; Masson E
J Clin Pharmacol; 2018 Apr; 58(4):485-493. PubMed ID: 29193123
[TBL] [Abstract][Full Text] [Related]
7. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
8. The Development of a PBPK Model for Atomoxetine Using Levels in Plasma, Saliva and Brain Extracellular Fluid in Patients with Normal and Deteriorated Kidney Function.
Alsmadi MM; Al Eitan LN; Idkaidek NM; Alzoubi KH
CNS Neurol Disord Drug Targets; 2022; 21(8):704-716. PubMed ID: 35043773
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions.
Storelli F; Desmeules J; Daali Y
CPT Pharmacometrics Syst Pharmacol; 2019 Aug; 8(8):567-576. PubMed ID: 31268632
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.
Kilford P; Khoshaein N; Southall R; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):699-710. PubMed ID: 35840839
[TBL] [Abstract][Full Text] [Related]
11. Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations.
Xu R; Tang H; Chen L; Ge W; Yang J
Br J Clin Pharmacol; 2021 Aug; 87(8):3244-3254. PubMed ID: 33528059
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
[TBL] [Abstract][Full Text] [Related]
13. Development and Verification of a Linked
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
[TBL] [Abstract][Full Text] [Related]
14. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
[TBL] [Abstract][Full Text] [Related]
15. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
[TBL] [Abstract][Full Text] [Related]
16. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
[TBL] [Abstract][Full Text] [Related]
17. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.
Ke AB; Nallani SC; Zhao P; Rostami-Hodjegan A; Isoherranen N; Unadkat JD
Drug Metab Dispos; 2013 Apr; 41(4):801-13. PubMed ID: 23355638
[TBL] [Abstract][Full Text] [Related]
18. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
19. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
